Key Takeaways Prescribers and pharmacies will submit prior authorization requests and claims to a CMS contractor, not Part D plans or their PBMs Detailed conditions for beneficiary eligibility specified Patients will have a copay of $50, but pharmacy reimbursement details remain to be specified Background on the BALANCE Model CMS announced the BALANCE Model in December of last year, in which CMS will negotiate directly with manufacturers on behalf of Part D plan sponsors and state Medicaid agencies for more favorable costs and terms for GLP-1 medications
See moreSafety Quality L-Carnitine is made with batch-tested, non-GMO ingredients, which are blended and packed at an independently certified facility
#MusculoskeletalOncology #OrthopaedicOncology #BoneAndSoftTissueTumors #OrthopaedicSurgery #MedicalEducation To view or add a comment, sign in
However, due to the infertility of the db/db and ob/ob mice (the most commonly used T2D models) [58, 59], they are not suitable for this study, and other T2D models with less reproductive injury are needed
Resources: Ying-Shi Zhang, Yi-Nuo Wang
Protective effect of shikimic acid against cisplatin-induced renal injury: in vitro and in vivo studies